Malignant Neoplasm of Breast
39
3
10
18
Key Insights
Highlights
Success Rate
90% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
5.1%
2 terminated out of 39 trials
90.0%
+3.5% vs benchmark
10%
4 trials in Phase 3/4
39%
7 of 18 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 18 completed trials
Clinical Trials (39)
Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases
A Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer (SYNTHESIS-Breast)
An Early Stress-Reduction Intervention in Patients With Newly Diagnosed Breast Cancer
A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer
Low-field MRI for Breast Cancer Screening
Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy
Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT
Selumetinib and Olaparib in Solid Tumors
Swedish Ibrance Registries Insights (SIRI)
TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast Cancer
Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors
A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer
MIRs 04 : Interpectoral Nerve Block With Ropivacaine Versus Placebo Before Breast Cancer Surgery
Ibrance Real World Insights
Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer
Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors
Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer
Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Trastuzumab (AryoTrust) Versus Herceptin® in Breast Cancer
Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO
Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer